
Novel SCD1 Inhibitors for Treatment of CancerAward last edited on: 5/15/2020
Sponsored Program
STTRAwarding Agency
NIH : NCITotal Award Amount
$2,279,000Award Phase
2Solicitation Topic Code
395Principal Investigator
John A CoplandCompany Information
Modulation Therapeutics Inc
One Medical Center Drive
Morgantown, WV 26506
Morgantown, WV 26506
(813) 786-2041 |
info@modulationtherapeutics.com |
www.modulationtherapeutics.com |
Research Institution
Mayo Clinic Rochester
Phase I
Contract Number: 1R41CA195946-01A1Start Date: 3/5/2016 Completed: 2/28/2017
Phase I year
2016Phase I Amount
$279,000Public Health Relevance Statement:
Public Health Relevance:
There are currently few treatment options for patients presenting with metastatic clear cell renal cell carcinoma, and developing novel strategies are required to improve patient outcomes. We recently discovered that Stearoyl CoA desaturase 1 (SCD1) was overexpressed in this deadly tumor. Moreover, data generated in our laboratory has shown that SCD1 expression promotes tumor growth and metastasis. To further test this novel strategy as a therapeutic approach, we developed potent SCD1 inhibitors. The goal of this proposal will be to i) define the therapeutic window and ii) utilize robust and well defined patien derived xenograft models to test the efficacy and potency of our lead SCD1 inhibitor.
Project Terms:
Address; advanced disease; Adverse effects; Affinity; Apoptosis; Attenuated; Biological Assay; Biological Availability; Biological Markers; cancer cell; cancer therapy; Cell Culture Techniques; Cell Line; Cell Proliferation; Cell Survival; Cells; chemotherapy; Chronic Disease; Clear Cell; Clinical; Clinical Trials; combinatorial; Data; Dependence; desaturase; design; Development; Disease; Dose; Drug Kinetics; Drug resistance; effective therapy; efficacy testing; Endoplasmic Reticulum; endoplasmic reticulum stress; Epithelial Cell Proliferation; Epithelial Cells; experience; FDA approved; Fibrous capsule of kidney; Gene Expression Profile; Genes; Goals; Growth; Human; Immune; Implant; improved; In Vitro; in vivo; inhibitor/antagonist; innovation; Kidney; Laboratories; Lead; Legal patent; Link; lipid biosynthesis; Luciferases; Lung; Malignant Neoplasms; Maximum Tolerated Dose; Measurement; Mediating; meetings; Messenger RNA; Metabolic Pathway; Metastatic to; Modeling; molecular marker; Mono-S; Monounsaturated Fatty Acids; mouse model; mTOR Inhibitor; Mus; Neoplasm Metastasis; novel; novel strategies; novel therapeutics; Oncogenes; Outcome; outcome forecast; overexpression; Pathway interactions; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; pre-clinical; Principal Investigator; Proteins; public health relevance; Publications; Publishing; Quality of life; Radiation; Renal Cell Carcinoma; Renal Tissue; Resected; Resistance; response; Sampling; Saturated Fatty Acids; Signal Pathway; Signal Transduction; Small Business Technology Transfer Research; small hairpin RNA; small molecule; Specimen; Staging; Stearoyl-CoA Desaturase; targeted treatment; Testing; Therapeutic; Therapeutic Agents; therapeutic evaluation; therapy design; Tissues; tool; Toxic effect; Toxicokinetics; Toxicology; tumor; Tumor Biology; tumor growth; tumor microenvironment; Tumor Tissue; tumor xenograft; tumorigenic; Xenograft Model; Xenograft procedure
Phase II
Contract Number: 2R42CA195946-02A1Start Date: 3/5/2016 Completed: 8/31/2020
Phase II year
2018(last award dollars: 2019)